These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 10683287)

  • 21. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
    Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Rose S; Ramsay Croft N; Jenner P
    Brain Res; 2007 Feb; 1133(1):110-4. PubMed ID: 17196564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL; Cheetham SC; Jenner P
    Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
    Thomas J; Wang J; Takubo H; Sheng J; de Jesus S; Bankiewicz KS
    Exp Neurol; 1994 Apr; 126(2):159-67. PubMed ID: 7925817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of desensitized nicotinic receptors on rotational behavior in a 6-hydroxydopamine model of Parkinson's disease.
    Han F; Wang H
    Neurosci Lett; 2007 Mar; 415(3):200-4. PubMed ID: 17270346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.
    Metz GA; Tse A; Ballermann M; Smith LK; Fouad K
    Eur J Neurosci; 2005 Aug; 22(3):735-44. PubMed ID: 16101755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
    Truong L; Allbutt HN; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):91-6. PubMed ID: 19007866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease.
    Forsback S; Niemi R; Marjamäki P; Eskola O; Bergman J; Grönroos T; Haaparanta M; Haapalinna A; Rinne J; Solin O
    Synapse; 2004 Feb; 51(2):119-27. PubMed ID: 14618679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
    Adams CE; Hoffman AF; Hudson JL; Hoffer BJ; Boyson SJ
    Exp Neurol; 1994 Dec; 130(2):261-8. PubMed ID: 7867755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
    Blunt S; Jenner P; Marsden CD
    Neuroscience; 1991; 40(2):453-64. PubMed ID: 1902916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
    Iancu R; Mohapel P; Brundin P; Paul G
    Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
    Glavan G; Zivin M
    Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
    Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
    Spinnewyn B; Charnet C; Cornet S; Roubert V; Chabrier PE; Auguet M
    Fundam Clin Pharmacol; 2011 Oct; 25(5):608-18. PubMed ID: 21077938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Ferger B
    Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.